Beth Marsh is stepping into the role of Neurotech Pharmaceuticals’ chief commercial officer (CCO) beginning April 28. Marsh will lead the organization, particularly as it prepares for the US launch of ...

Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine advanced therapy (RMAT) designation to treat X-linked ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications. The US Food and Drug ...

A new Chinese report recognized that social media smartphone application–based interventions significantly improved follow-up adherence and increased parental knowledge among families of children with ...

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission. Prevent Blindness has promoted five leaders to further its efforts and ...

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education. A new ...

Pykus Therapeutics announced it has completed enrollment in its pilot study, PYK-2101-RD00, evaluating PYK-2101, a focal hydrogel retinal sealant, in patients undergoing surgery for detached retina.

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME). Vantage ...

Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida. Retina World Congress 2025 will take place May ...

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.